Moderna and Merck have unveiled an mRNA-based cancer vaccine, Intismeran, which Al Jazeera reports showed promise in late-stage trials by reducing the recurrence and spread of melanoma.
Key facts
- Moderna and Merck unveiled an mRNA-based cancer vaccine named Intismeran, according to Al Jazeera.
- Al Jazeera reported the vaccine showed promise in reducing melanoma recurrence and spread in late-stage trials.
- The report did not provide figures on the size of the effect or the number of patients involved.
- The findings were reported by Al Jazeera on 19 August 2026.
Moderna and Merck have unveiled an mRNA-based cancer vaccine that Al Jazeera reports showed promise in reducing the recurrence and spread of melanoma. The vaccine is named Intismeran.
According to the report, the vaccine reduced both the likelihood of melanoma returning and its spread among patients in late-stage trials. Al Jazeera described the results as showing promise but did not detail the size of the effect or the number of patients involved.
Further details on regulatory timelines, availability, and full trial data were not provided in the source reporting. The two companies’ respective roles in the collaboration were not specified in the available report.
Why it matters
Cancer vaccines using mRNA technology are being closely watched as a potential new approach to treating aggressive cancers such as melanoma. Late-stage trial results are a key milestone for patients, doctors and investors, though the available reporting does not yet include full trial data or regulatory timelines.
Frequently asked questions
What is Intismeran?
Intismeran is Moderna's mRNA-based cancer vaccine, which according to Al Jazeera showed promise in late-stage trials by reducing melanoma recurrence and spread.
Which companies are behind the vaccine?
Moderna and Merck unveiled the mRNA-based cancer vaccine, according to Al Jazeera.
What did the trial results show?
According to Al Jazeera, late-stage trials showed the vaccine reducing melanoma recurrence and spread. Further figures were not provided in the source.